{"id":388122,"date":"2020-11-24T16:33:03","date_gmt":"2020-11-24T21:33:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388122"},"modified":"2020-11-24T16:33:03","modified_gmt":"2020-11-24T21:33:03","slug":"yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","title":{"rendered":"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Nov.  24, 2020  (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, Chief Executive Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference.<\/p>\n<p>Dr. Peters\u2019 presentation at the Piper Sandler conference will be available on-demand via the conference portal and through the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UfwH3A2-AOZY_UTZx9RoeiMBMaiJ7e-k-qoj6bf45dCplsNrqOsMKdnans8zpC1uw_LrLzSkpvkpvCYFPEelVhO_icZYtU0E58lM_sHrFhg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">yumanity.com\/events<\/a> beginning November 23, 2020.<\/p>\n<p>\n        <strong>About Yumanity<\/strong><br \/>\n        <strong>Therapeutics<\/strong><br \/>\n        <br \/>Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform allows the Company to rapidly screen for disease-modifying therapies to overcome toxicity of misfolded proteins in neurogenerative diseases. Yumanity\u2019s growing pipeline consists of additional programs focused on Lewy body dementia, amyotrophic lateral sclerosis (ALS), and Alzheimer\u2019s disease. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=szf2l9MiHrIdVZ9d30kv0mtMbxjcKFZQT96sVJV1dAs3hm0tS_MW9qKBkEr4TLZlzhkjb1czCLfCnwe6rQaN3A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.yumanity.com<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Burns McClellan, Inc.<br \/>John Grimaldi<br \/>jgrimaldi@burnsmc.com<br \/>(212) 213-0006<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Burns McClellan, Inc.<br \/>Ryo Imai \/ Robert Flamm, Ph.D.<br \/>rimai@burnsmc.com \/ rflamm@burnsmc.com<br \/>(212) 213-0006<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8e15fca8-9521-45af-9c88-f58332446031\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, Chief Executive Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference. Dr. Peters\u2019 presentation at the Piper Sandler conference will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning November 23, 2020. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388122","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, Chief Executive Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference. Dr. Peters\u2019 presentation at the Piper Sandler conference will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning November 23, 2020. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s &hellip; Continue reading &quot;Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference\",\"datePublished\":\"2020-11-24T21:33:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"},\"wordCount\":210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\",\"name\":\"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=\",\"datePublished\":\"2020-11-24T21:33:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","og_description":"BOSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, Chief Executive Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference. Dr. Peters\u2019 presentation at the Piper Sandler conference will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning November 23, 2020. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s &hellip; Continue reading \"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:33:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference","datePublished":"2020-11-24T21:33:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"},"wordCount":210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","name":"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=","datePublished":"2020-11-24T21:33:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgyOCMzODQyOTI4IzIyMDAzMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Yumanity Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388122"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388122\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}